Belite Bio, Inc. · NASDAQ:BLTE
Belite Bio — FY2023 Earnings Presentation
12 slides from Belite Bio's earnings presentation, Mar 12, 2024
Slide 1: 2023 Full-Year Financial Results Conference Call
2023 Full-Year Financial Results Conference Call March 12, 2024 Nasdaq: BLTE BELITE BIO / 1
Slide 2: Forward-Looking Statements and Legal Disclaimer
Forward-Looking Statements and Legal Disclaimer This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire,
Slide 3: Experienced Leadership Team
Experienced Leadership Team Belite Management Team Tom Lin, MMED, PhD, MBA Nathan Mata, PhD Hao-Yuan Chuang, CFA, MBA, FRM (Chairman, CEO) (CSO) (CFO) • 10+ years of executive management • 15+ years of ophthalmic drug • 13+ years of capital market roles in biotech development experience across exper
Slide 4: Belite Bio Pipeline Overview
Belite Bio Pipeline Overview PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NDA Stargardt Disease (STGD1) • Ph2 24-month final data continues to show slowing of lesion growth Tinlarebant • Ph3, 2-year treatment, global trial (“DRAGON” Study) is ongoing (completed enrollment, 104 subjects, age 12-20, interim (L
Slide 5: STGD1 Clinical Trials
STGD1 Clinical Trials BELITE BIO / 5
Slide 6: Clinical Trial Design Overview in STGD1
Tinlarebant (LBS-008) Clinical Trial Design Overview in STGD1 Reduction in Lesion Growth Rate (DDAF) as Measured by Retinal Imaging is the FDA Accepted Primary Endpoint in STGD1 and GA STGD1 Phase 2 “LBS-008-CT02” STGD1 “Dragon” Phase 3* (Preliminary 24-Month Interim Data Available) Enrollment 13 su
Slide 7: Ph2 24-month: Sustained Lower Lesion Growth Compared to ProgStar
Ph2 24-month: Sustained Lower Lesion Growth Compared to ProgStar Tinlarebant (LBS-008) • A comparison of incident DDAF lesion growth among ProgStar subjects with similar baseline characteristics as subjects in LBS-008-CT02 (i.e, ≤ 18 years old) was performed Growth of Incident DDAF Retinal Lesions L
Slide 8: Phase 3 Geographic Atrophy
Phase 3 Geographic Atrophy BELITE BIO / 8
Slide 9: Clinical Trial Design Overview in GA
Tinlarebant (LBS-008) Clinical Trial Design Overview in GA • Established Efficacy Endpoint – Reduction GA Phase 3 “Phoenix”* in lesion growth rate (DDAF) as measured Approximately 430 subjects targeted by retinal imaging is the FDA accepted Enrollment (Enrolling) primary endpoint for STGD1 and GA Si
Slide 10: 2023 Full-Year Financial Results
2023 Full-Year Financial Results For more info please visit: www.belitebio.com
Slide 11: 2023 Full-Year Financial Results
2023 Full-Year Financial Results (In thousand USD) For the year ended December 31 2022 2023 Total operating expenses 12,821 31,668 - R&D 8,869 24,844 - G&A 3,952 6,824 Net loss (12,844) (31,614) • Follow-on net proceeds: $27.3 million • Cash: $88.2 million BELITE BIO / 11
Slide 12: Q&A
Q&A For more info please visit: www.belitebio.com